News & Updates

Ask Us Anything – Medical Devices and Diagnostics

11/19/2020

Yesterday, we held our fifth virtual networking meeting in our ongoing series called Ask us Anything In Clinical Research. For our fifth meeting we covered the topic of Medical Device and Diagnostic studies. Our guest for this meeting was Eric Filion, Vice President of Sales for LOK North America – Medical Device Regulatory experts. Thank…

Read More

Hope Biosciences Stem Cell Research Foundation Selects Phlexglobal to Support Rapid, Compliant Investigational New Drug Application for COVID-19 Therapy

11/19/2020

Excerpt from the Press Release: Phlexglobal, a leading innovative technology and services provider for the life sciences industry, today announces that Hope Biosciences Stem Cell Research Foundation has selected Phlexglobal’s advanced SaaS solution, PhlexSubmission, to enhance the efficiency and quality of its eCTD submissions process. As an organization dedicated to advancing research through innovative protocols…

Read More

Werewolf Therapeutics Appoints Dr. Randi Isaacs as Chief Medical Officer

11/18/2020

Excerpt from the Press Release: CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ — Werewolf Therapeutics, Inc., an oncology biotherapeutics company developing next-generation, transformative cancer therapeutics, today announced the appointment of Randi Isaacs, M.D., as Chief Medical Officer. Dr. Isaacs brings to the Werewolf team more than 20 years’ experience as a hematologist and oncologist driving clinical…

Read More

Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2

11/17/2020

Excerpt from the Press Release: SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intravenous (IV) COVI-AMG (STI-2020) to treat COVID-19 patients with mild symptoms and to evaluate safety and pharmacokinetics in healthy volunteers. Sorrento has previously…

Read More

Stanford develops CRISPR ‘lab on a chip’ for detecting COVID-19

11/16/2020

Excerpt from the Article: Researchers at Stanford University have developed a CRISPR-based “lab on a chip” to detect COVID-19, and are working with automakers at Ford to develop their prototype into a market-ready product. This could provide an automated, hand-held device designed to deliver a coronavirus test result anywhere within 30 minutes. In a study…

Read More

Novel insights on cellular suicide could provide new avenues for cancer therapies

11/15/2020

Excerpt from the Article: Several years ago, biologist Denise Montell, a distinguished professor at UC Santa Barbara, found that sometimes cells survive after what was considered the critical step in cellular suicide. Now, she and her lab have identified two key factors involved in this remarkable recovery. The findings, published in Nature Communications, indicate that…

Read More

Innovative machine-learning approach for future diagnostic advances in Parkinson’s disease

11/14/2020

Excerpt from the Article: Parkinson’s disease (PD) is the second most common neurodegenerative disease, with patient numbers being expected to double worldwide in the next 20 years. The detailed molecular and cellular mechanisms underlying its pathogenesis remains unclear, although recent evidence has pointed towards the role of mitochondrial dysfunction in the onset of the disease.…

Read More

Scanning the horizon for future Covid-19 treatments

11/13/2020

Excerpt from the Article: Hopes of finding a magic bullet against Covid-19, at least within the next few months, rest on the outcomes of a small number of clinical trials. Beyond these leading antibody and vaccine approaches, few large clinical programmes of other novel mechanisms are under way. True, there is a huge amount of…

Read More

Innovative machine-learning approach for future diagnostic advances in Parkinson’s disease

11/12/2020

Excerpt from the Article: Parkinson’s disease (PD) is the second most common neurodegenerative disease, with patient numbers being expected to double worldwide in the next 20 years. The detailed molecular and cellular mechanisms underlying its pathogenesis remains unclear, although recent evidence has pointed towards the role of mitochondrial dysfunction in the onset of the disease.…

Read More

NeuroRx and Relief Therapeutics announce continuation of RLF-100™ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020

11/12/2020

Excerpt from the Press Release: RADNOR, Pa. and GENEVA, Nov. 5, 2020 /PRNewswire/ — NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCBB:RLFTF) (“Relief”) announced that the independent Data Monitoring Committee (DMC) met yesterday and voted unanimously that NCT 04311697 should continue as planned to its full enrollment of 165 patients.  Specifically, the committee identified no safety concerns…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives